BALAXI PHARMACEUTICALS LIMITED (NSE:BALAXI) — Market Cap & Net Worth
Market Cap & Net Worth: BALAXI PHARMACEUTICALS LIMITED (BALAXI)
BALAXI PHARMACEUTICALS LIMITED (NSE:BALAXI) has a market capitalization of $15.90 Million (Rs1.47 Billion) as of May 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #25690 globally and #1432 in its home market, demonstrating a -3.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BALAXI PHARMACEUTICALS LIMITED's stock price Rs26.63 by its total outstanding shares 55207500 (55.21 Million). Analyse cash flow conversion of BALAXI PHARMACEUTICALS LIMITED to see how efficiently the company converts income to cash.
BALAXI PHARMACEUTICALS LIMITED Market Cap History: 2015 to 2026
BALAXI PHARMACEUTICALS LIMITED's market capitalization history from 2015 to 2026. Data shows growth from $3.06 Million to $15.90 Million (24.45% CAGR).
BALAXI PHARMACEUTICALS LIMITED Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BALAXI PHARMACEUTICALS LIMITED's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
BALAXI PHARMACEUTICALS LIMITED's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.06x
BALAXI PHARMACEUTICALS LIMITED's market cap is 0.06 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.29 Million | $475.11K | -$803.73K | 4.82x | N/A |
| 2017 | $1.77 Million | $-6.14 Million | -$7.90 Million | -0.29x | N/A |
| 2018 | $3.40 Million | $-500.00 | -$7.72 Million | -6796.80x | N/A |
| 2019 | $9.68 Million | $135.95 Million | $19.66 Million | 0.07x | 0.49x |
| 2020 | $77.49 Million | $456.32 Million | $61.04 Million | 0.17x | 1.27x |
| 2021 | $61.18 Million | $2.31 Billion | $381.37 Million | 0.03x | 0.16x |
| 2022 | $72.51 Million | $2.79 Billion | $476.58 Million | 0.03x | 0.15x |
| 2023 | $51.63 Million | $3.36 Billion | $459.62 Million | 0.02x | 0.11x |
| 2024 | $43.17 Million | $2.41 Billion | -$23.87 Million | 0.02x | N/A |
| 2025 | $16.04 Million | $2.89 Billion | $250.70 Million | 0.01x | 0.06x |
Competitor Companies of BALAXI by Market Capitalization
Companies near BALAXI PHARMACEUTICALS LIMITED in the global market cap rankings as of May 4, 2026.
Key companies related to BALAXI PHARMACEUTICALS LIMITED by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BALAXI PHARMACEUTICALS LIMITED Historical Marketcap From 2015 to 2026
Between 2015 and today, BALAXI PHARMACEUTICALS LIMITED's market cap moved from $3.06 Million to $ 15.90 Million, with a yearly change of 24.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs15.90 Million | -0.89% |
| 2025 | Rs16.04 Million | -62.84% |
| 2024 | Rs43.17 Million | -16.38% |
| 2023 | Rs51.63 Million | -28.80% |
| 2022 | Rs72.51 Million | +18.51% |
| 2021 | Rs61.18 Million | -21.05% |
| 2020 | Rs77.49 Million | +700.37% |
| 2019 | Rs9.68 Million | +184.91% |
| 2018 | Rs3.40 Million | +91.92% |
| 2017 | Rs1.77 Million | -22.66% |
| 2016 | Rs2.29 Million | -25.15% |
| 2015 | Rs3.06 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of BALAXI PHARMACEUTICALS LIMITED was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.90 Million USD |
| MoneyControl | $15.90 Million USD |
| MarketWatch | $15.90 Million USD |
| marketcap.company | $15.90 Million USD |
| Reuters | $15.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. The company offers pharmaceutical products across various therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes. The company was fo… Read more